메뉴 건너뛰기




Volumn 366, Issue 23, 2012, Pages 2189-2197

Combination chemotherapy in advanced adrenocortical carcinoma

(37)  Fassnacht, Martin a   Terzolo, Massimo b   Allolio, Bruno a   Baudin, Eric c   Haak, Harm d   Berruti, Alfredo b   Welin, Staffan e   Schade Brittinger, Carmen f   Lacroix, André g   Jarzab, Barbara h   Sorbye, Halfdan i   Torpy, David J j   Stepan, Vinzenz k   Schteingart, David E l   Arlt, Wiebke m   Kroiss, Matthias a   Leboulleux, Sophie c   Sperone, Paola b   Sundin, Anders n   Hermsen, Ilse d   more..


Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID; MITOTANE; STREPTOZOCIN;

EID: 84861888600     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1200966     Document Type: Article
Times cited : (649)

References (34)
  • 1
    • 66749185880 scopus 로고    scopus 로고
    • Prevalence and incidence of endocrine and metabolic disorders in the United States: A comprehensive review
    • Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009;94:1853-78.
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 1853-1878
    • Golden, S.H.1    Robinson, K.A.2    Saldanha, I.3    Anton, B.4    Ladenson, P.W.5
  • 2
    • 33646593777 scopus 로고    scopus 로고
    • Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress?
    • DOI 10.1007/s00268-005-0329-x
    • Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006;30:872-8. (Pubitemid 43724119)
    • (2006) World Journal of Surgery , vol.30 , Issue.5 , pp. 872-878
    • Kebebew, E.1    Reiff, E.2    Duh, Q.-Y.3    Clark, O.H.4    McMillan, A.5
  • 6
    • 59449084843 scopus 로고    scopus 로고
    • Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a revised TNM classification
    • Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 2009;115:243-50.
    • (2009) Cancer , vol.115 , pp. 243-250
    • Fassnacht, M.1    Johanssen, S.2    Quinkler, M.3
  • 7
    • 76049095621 scopus 로고    scopus 로고
    • The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer staging system: A North American validation
    • Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer staging system: a North American validation. Eur J Cancer 2010;46:713-9.
    • (2010) Eur J Cancer , vol.46 , pp. 713-719
    • Lughezzani, G.1    Sun, M.2    Perrotte, P.3
  • 9
    • 0035883416 scopus 로고    scopus 로고
    • Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma
    • DOI 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2
    • Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001;92:1385-92. (Pubitemid 32947821)
    • (2001) Cancer , vol.92 , Issue.6 , pp. 1385-1392
    • Baudin, E.1    Pellegriti, G.2    Bonnay, M.3    Penfornis, A.4    Laplanche, A.5    Vassal, G.6    Schlumberger, M.7
  • 11
    • 34249810952 scopus 로고    scopus 로고
    • Adrenocortical cancer: Pathophysiology and clinical management
    • DOI 10.1677/erc.1.01130
    • Libé R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007;14:13-28. (Pubitemid 47521719)
    • (2007) Endocrine-Related Cancer , vol.14 , Issue.1 , pp. 13-28
    • Libe, R.1    Fratticci, A.2    Bertherat, J.3
  • 13
    • 80053312970 scopus 로고    scopus 로고
    • Contemporary management of adrenocortical carcinoma
    • Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol 2011;60:1055-65.
    • (2011) Eur Urol , vol.60 , pp. 1055-1065
    • Zini, L.1    Porpiglia, F.2    Fassnacht, M.3
  • 14
    • 83955165239 scopus 로고    scopus 로고
    • Therapeutic management of advanced adrenocortical carcinoma: What do we know in 2011?
    • Baudin E, Leboulleux S, Al Ghuzlan A, et al. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer 2011;2:363-71.
    • (2011) Horm Cancer , vol.2 , pp. 363-371
    • Baudin, E.1    Leboulleux, S.2    Al Ghuzlan, A.3
  • 16
    • 0032533913 scopus 로고    scopus 로고
    • Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma
    • DOI 10.1002/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0. CO;2-3
    • Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer 1998;83:2194-200. (Pubitemid 28525402)
    • (1998) Cancer , vol.83 , Issue.10 , pp. 2194-2200
    • Berruti, A.1    Terzolo, M.2    Pia, A.3    Angeli, A.4    Dogliotti, L.5
  • 17
    • 0033767891 scopus 로고    scopus 로고
    • Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: Long-term survival in its adjuvant use
    • Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000;11:1281-7.
    • (2000) Ann Oncol , vol.11 , pp. 1281-1287
    • Khan, T.S.1    Imam, H.2    Juhlin, C.3
  • 19
    • 0034949971 scopus 로고    scopus 로고
    • Interpreting quality of life data: Population-based reference data for the EORTC QLQ-C30
    • DOI 10.1016/S0959-8049(01)00127-7, PII S0959804901001277
    • Fayers PM. Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur J Cancer 2001;37:1331-4. (Pubitemid 32588741)
    • (2001) European Journal of Cancer , vol.37 , Issue.11 , pp. 1331-1334
    • Fayers, P.M.1
  • 20
    • 33646783722 scopus 로고    scopus 로고
    • v2.0. Bethesda, MD: Cancer Therapy Evaluation Program
    • Common Terminology Criteria for Adverse Events (CTCAE) v2.0. Bethesda, MD: Cancer Therapy Evaluation Program, 1999 (http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm).
    • (1999) Common Terminology Criteria for Adverse Events (CTCAE)
  • 21
    • 77956352930 scopus 로고    scopus 로고
    • Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma
    • Malandrino P, Al Ghuzlan A, Castaing M, et al. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 2010;17:797-807.
    • (2010) Endocr Relat Cancer , vol.17 , pp. 797-807
    • Malandrino, P.1    Al Ghuzlan, A.2    Castaing, M.3
  • 23
    • 80054769146 scopus 로고    scopus 로고
    • Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma
    • Oxf
    • Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2011;75:585-91.
    • (2011) Clin Endocrinol , vol.75 , pp. 585-591
    • Kroiss, M.1    Quinkler, M.2    Lutz, W.K.3    Allolio, B.4    Fassnacht, M.5
  • 24
    • 79956306619 scopus 로고    scopus 로고
    • Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: Results of a retrospective ENS@T multicenter study
    • Hermsen IG, Fassnacht M, Terzolo M, et al. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011;96:1844-51.
    • (2011) J Clin Endocrinol Metab , vol.96 , pp. 1844-1851
    • Hermsen, I.G.1    Fassnacht, M.2    Terzolo, M.3
  • 26
    • 0034162574 scopus 로고    scopus 로고
    • Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: A Southwest Oncology Group study
    • DOI 10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0. CO;2-R
    • Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000;88:1159-65. (Pubitemid 30127678)
    • (2000) Cancer , vol.88 , Issue.5 , pp. 1159-1165
    • Williamson, S.K.1    Lew, D.2    Miller, G.J.3    Balcerzak, S.P.4    Baker, L.H.5    Crawford, E.D.6
  • 27
    • 0036569569 scopus 로고    scopus 로고
    • A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist
    • DOI 10.1002/cncr.10487
    • Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002;94:2333-43. (Pubitemid 34457113)
    • (2002) Cancer , vol.94 , Issue.9 , pp. 2333-2343
    • Abraham, J.1    Bakke, S.2    Rutt, A.3    Meadows, B.4    Merino, M.5    Alexander, R.6    Schrump, D.7    Bartlett, D.8    Choyke, P.9    Robey, R.10    Hung, E.11    Steinberg, S.M.12    Bates, S.13    Fojo, T.14
  • 32
    • 75149143015 scopus 로고    scopus 로고
    • Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
    • Wortmann S, Quinkler M, Ritter C, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 2010;162:349-56.
    • (2010) Eur J Endocrinol , vol.162 , pp. 349-356
    • Wortmann, S.1    Quinkler, M.2    Ritter, C.3
  • 33
    • 65749120532 scopus 로고    scopus 로고
    • New targets and therapeutic approaches for endocrine malignancies
    • Fassnacht M, Kreissl MC, Weismann D, Allolio B. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 2009;123:117-41.
    • (2009) Pharmacol Ther , vol.123 , pp. 117-141
    • Fassnacht, M.1    Kreissl, M.C.2    Weismann, D.3    Allolio, B.4
  • 34
    • 84857943100 scopus 로고    scopus 로고
    • Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma
    • Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 2012;166:451-8.
    • (2012) Eur J Endocrinol , vol.166 , pp. 451-458
    • Berruti, A.1    Sperone, P.2    Ferrero, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.